ADMdx presents the results of our collaborative work with Siemens Healthcare in quantifying the effects of PET image reconstruction on measured amyloid burden.

ADMdx presented its work in applications of machine learning to critical drug development questions at the American College of Neuropsychopharmacology (ACNP) Conference held in Palm Springs, CA, on December 5, 2017.  Examples presented included differentiation of dementias, prediction of cognitive decline, and dose-response of two neuropsychiatric therapeutics.

Results of our application of machine learning to the DIAN early-onset Alzheimer’s disease data set were presented at the Clinical Trials in Alzheimer’s Disease on November 2, 2017, in Boston, MA.

ADMdx to present findings in tau imaging at the 2017 Alzheimer’s Association International Conference (AAIC). This work identifies relationships between the emergence of AD-related hypometabolism, amyloid status, and tau burden across the spectrum of preclinical, prodromal, and dementia stage Alzheimer’s disease.

Dawn Matthews to speak at Traumatic Brain Injury (TBI) symposium, where she will describe Opportunities and Challenges in imaging of TBI. The symposium is focused on the need for initiatives in the diagnosis and treatment of the brain trauma occurring in athletes, military, and other personnel.

ADMdx to present impact of amyloid PET scan alignment on amyloid measurement at the Human Amyloid Imaging (HAI) Meeting. This work, conducted in collaboration with Siemens Healthineers and sponsored through a grant from the Radiologic Society of North America (RSNA), is the first to quantify the error introduced into amyloid measurement due to subject motion.

ADMdx selected as one of 12 Innovator Companies for 2016 by PM360, a journal specializing in the pharmaceutical industry.  This award highlights ADMdx’s novel advances in the detection and differentiation of dementias, and in the evaluation of treatment effects upon disease progression.

ADMdx presents at the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board meeting on machine learning and early-frame amyloid PET to measure neuronal activity based on cerebral blood flow. Our technology optimizes the information obtained from the first few minutes after injection of amyloid PET tracers such as florbetapir. Information about neurodegeneration and amyloid burden can thus be obtained from the same scan.

ADMdx’s analysis of tau PET in Down Syndrome patients with emerging Alzheimer’s disease to be presented on December 5 at CTAD 2016.  Dr. Michael Rafii, Principal Investigator of the Down Syndrome Biomarker Initiative (DSBI) study, will present ADMdx’s analysis of tau PET image data in adult patients with Down Syndrome at CTAD. This analysis showed a striking association between the presence of tau as measured using the PET tracer AV1451 (Avid Radiopharmaceuticals) and amyloid positivity, and is the first to report findings in DS adults using AV-1451.

ADMdx participates in Alzheimer’s Association Greater Illinois Chapter Annual Research Symposium, an important intersection of research and clinical care ADMdx exhibited at the Annual Scientific Symposium held by the Greater Illinois Chapter of the Alzheimer’s Association.  Focus was on the diagnosis and clinical management of Alzheimer’s disease, including the integration of imaging biomarkers into clinical assessment. The symposium included several excellent talks from members of Northwestern University, Rush Medical Center, and other institutions.  The strong attendance and interest shown by caregivers, patients, and the medical community reflected the importance of education, access to information and care, and the advancement of diagnostic and therapeutic approaches in dementia.